The Effect of Turmeric Extract on the Treatment of Patients with Covid-19

Comparison of the Effect of Turmeric Extract and Placebo Capsule on Alpha Tumor Necrosis Factor (TNF-a) Inflammatory Factor Interleukin-6 (IL-6) and Inflammatory Factor 1-Beta (IL-1ß) in Patients with Covid-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201111049348N2

Enrollment

120

Registered

2021-02-25

Start date

2021-02-28

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

People with COVID 19 whose disease has been confirmed by Real Time PCR.. Virus identified

Interventions

Intervention 1: Alcoholic extract of turmeric will be purchased from Zarband Company and will be received in sterile packages. Prior to purchase, the manufacturer will receive a Certificate of Sale an

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Includes people with laboratory confirmation of Quid 19 virus regardless of clinical signs and close association Age over 15 years

Exclusion criteria

Exclusion criteria: History of drug allergies History of allergies Patients with immunodeficiency Patients with hypertension Group of patients with underlying disease

Design outcomes

Primary

Measure	Time frame
Interleukin 6( IL-6). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.;Interleukin One Beta( IL-1ß). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.;Alpha tumor necrosis factor(TNF-a). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.	—

Measure

Time frame

Interleukin 6( IL-6). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.;Interleukin One Beta( IL-1ß). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.;Alpha tumor necrosis factor(TNF-a). Timepoint: Measurements of variable are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit.

—

Secondary

Measure	Time frame
The international normalized ratio (INR). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;D -Dimmer. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;Fibrinogen. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;Ferritin. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;C Reactive Protein (CRP). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.	—

Measure

Time frame

The international normalized ratio (INR). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;D -Dimmer. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;Fibrinogen. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;Ferritin. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.;C Reactive Protein (CRP). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMrs Shokofe Noori

Shahid Beheshti University of Medical Sciences

shnoori85@yahoo.com+98 21 2387 2570

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026